NCT02460354

Metformin and Congenital Nephrogenic Diabetes Insipidus

Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).

Detailed description

Nephrogenic diabetes insipidus (NDI) is a genetic disease. Patients with this disease make large amounts of urine because their kidneys don't hold on to water. The large amount of urine means that patients need to urinate very frequently. They are also at increased risk for dehydration if they don't drink enough. The large amount of urine can sometimes damage their bladders and kidneys. There are some medicines that may help these patients urinate less, but they are not very effective. There is evidence in animal studies that a medication called metformin may help patients with NDI urinate less.

Conditions

• Diabetes Insipidus

Interventions

Type	Name	Description
DRUG	Metformin	Metformin 500 mg pill dispensed once orally

Timeline

• Start date: 2015-09-01
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2015-06-02
• Last updated: 2018-07-17

Locations

3 sites across 1 country: United States